Milestone Pharmaceuticals (MIST) Accounts Payables (2018 - 2026)

Milestone Pharmaceuticals (MIST) has 9 years of Accounts Payables data on file, last reported at $10.0 million in Q1 2026.

• Quarterly Accounts Payables rose 320.43% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (up 320.43% YoY) and the FY2025 annual result came in at $5.6 million, down 25.28% from the prior year.
• Accounts Payables improved to $10.0 million in Q1 2026, from $5.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $10.0 million in Q3 2025 to a low of $1.7 million in Q1 2024.
• A 5-year average of $5.6 million and a median of $5.6 million in 2025 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables sank 76.73% — and 2026, when it soared 320.43%.
• Tracing MIST's Accounts Payables over 5 years: stood at $5.6 million in 2022, then advanced by 18.36% to $6.7 million in 2023, then advanced by 13.1% to $7.6 million in 2024, then dropped by 25.28% to $5.6 million in 2025, then soared by 77.56% to $10.0 million in 2026.
• The last three Accounts Payables figures came in at $10.0 million (Q1 2026), $5.6 million (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.